Breast Imaging

What Is the Best Initial Imaging for a New Palpable Bilateral Axillary Lump?

·
What Is the Best Initial Imaging for a New Palpable Bilateral Axillary Lump?

A 42-year-old female presents to your clinic for evaluation of new, tender lumps she discovered in both armpits last week. On examination, you confirm palpable, mobile, soft tissue fullness bilaterally in the axillae. She has no personal history of breast cancer and is otherwise healthy, though she reports having a significant upper respiratory infection about a month ago. You need to determine the most appropriate initial imaging study to evaluate these findings. This article provides a detailed clinical workflow for this specific scenario, guiding you through the differential diagnosis, imaging rationale, and downstream decision-making based on the American College of Radiology (ACR) Appropriateness Criteria. For this presentation, the ACR rates US axilla as Usually appropriate.

Who Fits This Clinical Scenario for Bilateral Axillary Lumps?

This guidance is specifically for a female patient presenting with new, palpable, and bilateral axillary lumps who is undergoing initial imaging evaluation. The key features are the new onset of the finding and its presence in both axillae simultaneously. This clinical context is distinct from several related, but different, scenarios that require a separate diagnostic approach.

This workflow does not apply if:

  • The lump is unilateral. A new palpable, unilateral axillary lump carries a different differential diagnosis, with a higher index of suspicion for a localized process, including primary breast malignancy.
  • The patient has a known breast cancer diagnosis. In patients with newly diagnosed breast cancer, axillary imaging is performed for staging purposes to assess for nodal metastases, not for the initial workup of a palpable finding. The imaging choice depends on tumor size and clinical node status.
  • The patient is undergoing neoadjuvant chemotherapy. Axillary imaging in this context is used to monitor treatment response in previously identified metastatic lymph nodes and follows a distinct set of guidelines.

Correctly identifying your patient’s specific clinical situation is the critical first step to ensure the right imaging test is ordered.

What Diagnoses Are You Working Up with Bilateral Axillary Lumps?

The bilateral nature of the palpable lumps significantly influences the differential diagnosis, pointing more toward systemic or benign conditions rather than a primary focal malignancy. The imaging workup is designed to differentiate among these possibilities.

The most common cause of bilateral axillary fullness or lumps is reactive lymphadenopathy. This is a benign enlargement of lymph nodes in response to a systemic process. Common triggers include recent viral or bacterial infections (such as mononucleosis or upper respiratory infections), recent vaccinations (including influenza or COVID-19), or underlying systemic inflammatory or autoimmune conditions. These nodes are typically mobile and may be tender.

Another frequent and benign consideration is accessory axillary breast tissue. This is normal breast tissue that extends into the axilla along the embryonic milk line, sometimes referred to as the axillary tail of Spence. This tissue can become more prominent, palpable, or tender in response to hormonal fluctuations, such as during the menstrual cycle, pregnancy, or lactation.

Less commonly, bilateral axillary lumps can be the initial presentation of a systemic malignancy, such as lymphoma or leukemia. In these cases, the lymph nodes may feel more firm or matted together. While less frequent than reactive causes, this is a critical diagnosis to exclude.

Finally, while metastatic disease from an unknown primary (including breast cancer) can present with axillary adenopathy, a bilateral presentation as the first sign is uncommon. However, it remains a consideration in the differential, particularly in older patients or those with other concerning systemic symptoms.

Why Is Axillary Ultrasound the Recommended First Study for This Presentation?

The ACR designates US axilla as Usually appropriate for the initial evaluation of new, palpable, bilateral axillary lumps. This recommendation is based on the modality’s high diagnostic utility, safety profile, and ability to guide subsequent management effectively in this specific clinical context.

Ultrasound is the ideal first-line tool because it excels at characterizing soft tissue structures and lymph nodes. It can readily distinguish between solid and cystic masses, identify accessory breast tissue by its characteristic echotexture, and evaluate the morphology of lymph nodes. Key features assessed on ultrasound include a lymph node’s size, shape (oval vs. round), cortical thickness, and the presence or absence of a normal fatty hilum. Benign reactive nodes typically retain their oval shape and fatty hilum, whereas malignant nodes often become rounded with a thickened cortex and loss of the hilum. This morphologic detail is crucial for risk stratification.

Furthermore, ultrasound involves no ionizing radiation (O 0 mSv) and does not require intravenous contrast, making it an exceptionally safe and well-tolerated examination. If a suspicious node is identified, ultrasound provides real-time guidance for a percutaneous biopsy, such as a fine-needle aspiration (FNA) or core needle biopsy, allowing for a definitive tissue diagnosis in the same session or a subsequent appointment.

Other imaging modalities are rated lower for this initial workup:

  • Mammography diagnostic and Digital breast tomosynthesis diagnostic are both rated Usually not appropriate. While these can visualize the axilla, they are less sensitive than ultrasound for detailed lymph node characterization. They also expose the patient to a small amount of ionizing radiation (☢☢ 0.1-1mSv) without adding significant diagnostic information for this specific problem.
  • MRI breast without and with IV contrast is also rated Usually not appropriate. MRI is a highly sensitive but less specific and more resource-intensive test. It is considered overkill for the initial evaluation of bilateral axillary lumps and is better reserved for problem-solving after initial imaging or for high-risk breast cancer screening.

What’s the Next Step After an Axillary Ultrasound?

The results of the axillary ultrasound will directly guide the downstream clinical workflow. The decision tree branches based on whether the findings are clearly benign, suspicious, or indeterminate.

If the ultrasound demonstrates benign-appearing reactive lymph nodes (e.g., symmetrically enlarged nodes with preserved oval shape and fatty hila) and the clinical history is consistent with a recent infection or vaccination, the appropriate next step is typically clinical observation. A follow-up clinical exam in 4 to 6 weeks is often recommended to ensure the nodes are decreasing in size. No further immediate imaging is usually required.

If the ultrasound identifies tissue consistent with accessory axillary breast tissue with no suspicious features, the patient can be reassured. Depending on her age and risk factors, a screening mammogram may be recommended if she is due, to provide a comprehensive baseline evaluation of all breast tissue.

If the ultrasound reveals one or more suspicious-appearing lymph nodes (e.g., rounded, with a thickened cortex, loss of the fatty hilum, or abnormal vascularity), the definitive next step is a tissue diagnosis. An ultrasound-guided core needle biopsy is the procedure of choice to obtain a histologic sample for pathologic evaluation.

In the rare case that the ultrasound is negative or non-diagnostic but a distinct, concerning lump persists on clinical examination, a referral to a breast surgeon for further evaluation is warranted. The surgeon may recommend a short-term follow-up exam or consider an excisional biopsy.

Common Pitfalls to Avoid in This Scenario

Navigating the workup for bilateral axillary lumps requires careful attention to the clinical context to avoid common errors in diagnosis and management.

One major pitfall is prematurely ordering advanced imaging. Starting with CT or MRI for this presentation is contrary to ACR guidelines, exposes the patient to unnecessary radiation or cost, and can lead to incidental findings that complicate the diagnostic picture. Ultrasound is the correct first step.

Another error is failing to correlate with clinical history. A recent history of a viral illness, systemic inflammation, or vaccination is a powerful clue pointing toward a benign reactive process. Overlooking this context can lead to unnecessary anxiety and workup.

A third pitfall is inadequate follow-up for presumed benign findings. If an ultrasound suggests reactive adenopathy, it is crucial to confirm clinical resolution. If the lumps persist or enlarge on follow-up, the diagnosis should be reconsidered, and further evaluation, potentially including biopsy, may be necessary.

If you encounter a suspicious node on ultrasound or if the clinical and imaging findings are discordant (e.g., a normal ultrasound but a highly concerning palpable mass), escalate care by referring the patient to a breast specialist or surgeon for definitive management.

Related ACR Topics and Tools

For a comprehensive overview of all clinical scenarios related to axillary imaging, further reading and specialized tools can provide additional context and support for your clinical decisions.

Frequently Asked Questions

Should I order a mammogram along with the axillary ultrasound?

For this specific scenario—new, palpable, bilateral axillary lumps—the ACR rates mammography as ‘Usually not appropriate’ for the initial workup. The primary goal is to characterize the axillary finding, for which ultrasound is superior. A screening mammogram may be appropriate if the patient is due based on standard screening guidelines, but it is not the primary diagnostic tool for the palpable axillary lumps themselves.

What if the patient recently had a COVID-19 or flu vaccine?

This is a critical piece of clinical history. Both COVID-19 and influenza vaccines are well-known causes of temporary, benign reactive axillary lymphadenopathy, which is often bilateral. If the ultrasound findings are consistent with reactive nodes and the patient was recently vaccinated, the standard recommendation is clinical follow-up in 4-6 weeks to ensure resolution, avoiding unnecessary biopsies.

If the ultrasound shows accessory breast tissue, does that increase the patient’s cancer risk?

Accessory axillary breast tissue is a normal anatomic variant and, by itself, does not significantly increase a patient’s overall risk for breast cancer. However, like any breast tissue, it is susceptible to the same benign and malignant processes. If the ultrasound is reassuring for normal accessory tissue, no further action is needed. The patient should continue with her routine breast cancer screening as recommended for her age and risk profile.

When should I suspect lymphoma in a patient with bilateral axillary lumps?

While less common than reactive adenopathy, lymphoma should be considered, especially if the patient has associated ‘B symptoms’ (fever, night sweats, unexplained weight loss) or if the nodes feel firm, rubbery, or matted on exam. On ultrasound, lymphomatous nodes may appear rounded and hypoechoic with a loss of the normal fatty hilum. If there is any clinical or sonographic suspicion, an ultrasound-guided core biopsy is necessary for diagnosis.

What if the lumps are painful? Does that change the workup?

Tenderness or pain is more commonly associated with benign inflammatory or reactive processes than with malignancy. The presence of pain can be a reassuring sign, but it does not eliminate the need for a proper workup. The recommended initial imaging remains an axillary ultrasound to characterize the underlying cause. The pain is a clinical feature to be considered alongside the imaging findings.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026